# A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

> **NCT03093324** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 506 (actual)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** ALKS 8700
- **DRUG:** Dimethyl Fumarate

## Key facts

- **NCT ID:** NCT03093324
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-15
- **Primary completion:** 2019-06-27
- **Final completion:** 2019-06-27
- **Target enrollment:** 506 (ACTUAL)
- **Last updated:** 2020-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093324, "A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03093324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*